### **3** UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

Т	Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									
Reminder: Rep owned directly		ate line for ea	ch class of securities benefic	cially S	EC 1473 (7-02	)			
Common St	ock		4,122 <u>(1)</u>		D	Â			
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)	of Securities Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	I		
(City)	(State)	(Zip)	Table I -	Non-Derivat	ive Securiti	es Be	neficially Owned		
(Street) BRAINTREE, MA 02184				.e			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
400 WOOD ROAD				(Check all applicable)					
(Last)	(First)	(Middle)	07/27/2017	4. Relationshi Person(s) to I	ip of Reporting ssuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
1. Name and Address of Reporting Person <u>*</u> Scanlan Jacqueline			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]					

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Securities U	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D) or Indirect	

OMB APPROVAL

3235-0104

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average burden hours per

#### Edgar Filing: Scanlan Jacqueline - Form 3

				Shares	(I) (Instr. 5)	
Non-qualified Stock Option (Right to Buy)	03/06/2018	03/06/2024	Common Stock	5,197 <u>(2)</u> \$ 38.43	D	Â
Non-qualified Stock Option (Right to Buy)	06/06/2018	06/06/2024	Common Stock	11,558 <u>(2)</u> \$ 41.64	D	Â

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Scanlan Jacqueline 400 WOOD ROAD BRAINTREE, MA 02184	Â	Â	SVP, Global Human Resources	Â		
Signatures						
/s/ Alexander P. Steffan, attorney-in-fact for Ms.			08/07/2017			

Scanlan <u>\*\*</u>Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- (2) Grant of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.